Cargando…

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

Monoclonal antibodies targeting CD38 are important for treatment of both newly diagnosed and relapsed multiple myeloma (MM). Daratumumab and isatuximab are anti-CD38 antibodies with the US Food and Drugs Administration approval in multiple different combinations. Despite good initial efficacy, patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez de Acha, Olivia, Reiman, Lauren, Jayabalan, David S., Walker, Zachary J., Bosma, Grace, Keller, Alana L., Parzych, Sarah E., Abbott, Diana, Idler, Beau M., Ribadeneyra, Drew, Niesvizky, Ruben, Forsberg, Peter A., Mark, Tomer M., Sherbenou, Daniel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598487/ https://www.ncbi.nlm.nih.gov/pubmed/37648670 http://dx.doi.org/10.1182/bloodadvances.2023010162

Ejemplares similares

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
por: Pouleau, Blandine, et al.
Publicado: (2023)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
por: Mouhieddine, Tarek H., et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023)

Activated protein C modulates T-cell metabolism and epigenetic FOXP3 induction via α-ketoglutarate
por: Gupta, Dheerendra, et al.
Publicado: (2023)

Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease
por: Kinoshita, Hannah, et al.
Publicado: (2022)

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
por: Keller, Michael D., et al.
Publicado: (2020)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

Catch those antibodies before they fall
por: Shaz, Beth H., et al.
Publicado: (2020)

Expanding the toolbox to combat a pandemic
por: Prockop, Susan E.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification
por: Martín Merinero, Hector, et al.
Publicado: (2021)

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
por: Nicolai, Leo, et al.
Publicado: (2022)

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
por: Botta, Cirino, et al.
Publicado: (2022)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice
por: Pletinckx, Katrien, et al.
Publicado: (2022)

Neutrophil transit time and localization within the megakaryocyte define morphologically distinct forms of emperipolesis
por: Huang, Frank Y., et al.
Publicado: (2022)

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases
por: Martin Merinero, Héctor, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome
por: Kumar, Deepak, et al.
Publicado: (2022)

Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors
por: Tamaki, Masaharu, et al.
Publicado: (2022)

4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
por: Swatler, Julian, et al.
Publicado: (2022)

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8(+) T cells into B-cell follicles during HIV-1 infection
por: Ogunshola, Funsho J., et al.
Publicado: (2022)

Altered microbiota-host metabolic cross talk preceding neutropenic fever in patients with acute leukemia
por: Rashidi, Armin, et al.
Publicado: (2021)

Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma
por: Ferrari, Nicola, et al.
Publicado: (2021)

Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model
por: Rafiei Hashtchin, Anna, et al.
Publicado: (2021)

An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies
por: Roider, Tobias, et al.
Publicado: (2021)

CD34(+)CD19(−)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
por: Bueno, Clara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pk5ehs7te7261elpabtfvbd3gh